The preparation and characteristics of sterically stabilized liposomes containing paclitaxel and super-paramagnetic iron oxide nanoparticles

doi:10.5246/jcps.2016.08.063

Journal of Chinese Pharmaceutical Sciences ›› 2016, Vol. 25 ›› Issue (8): 570-575.DOI: 10.5246/jcps.2016.08.063

• Original articles • Previous Articles Next Articles

The preparation and characteristics of sterically stabilized liposomes containing paclitaxel and super-paramagnetic iron oxide nanoparticles

Wei Ren^1,2, Shuang Zhang^1,2, Ting Zhong^1,2, Dan Huang^1,2, Xin Yao^1,2, Yang Guo^1,2, Xiaochuan Duan^1,2, Yifan Yin², Shushi Zhang², Xuan Zhang^1,2*

1. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2016-05-15 Revised:2016-05-29 Online:2016-09-01 Published:2016-06-12
Contact: Tel.: +86-010-82805928, E-mail: xuanzhang@bjmu.edu.cn
Supported by:
Specialized Research Fund for the Doctoral Program of Higher Education (Grant No. 20120001110012).

Abstract

Abstract:

Theranostics, combining therapy and diagnosis, is an appealing approach for chemotherapy. In the present study, we selected paclitaxel (PTX) as a therapeutic agent, super-paramagnetic iron oxide nanoparticles (SPIO) as a diagnostic agent and sterically stabilized liposomes as a carrier to prepare theranostic liposomes. The SPIO were prepared and characterized. Moreover, the sterically stabilized liposomes containing PTX and SPIO (PTX/SPIO-SSL) were prepared. The characteristics of PTX/SPIO-SSL were investigated. The results indicated that prepared SPIO exhibited super-paramagnetic and could be used for MRI. The average particle size of PTX/SPIO-SSL was about 170 nm, with a polydispersity index (PDI) less than 0.3. The zeta potential of PTX/SPIO-SSL was negative. The PTX entrapment efficiency of PTX/SPIO-SSL was more than 98%. The TEM results indicated the spherical structure and dense SPIO content in PTX/SPIO-SSL. The in vitro release of PTX from PTX/SPIO-SSL and PTX-SSL was almost identical at both pH 6.8 and 7.4. In conclusion, the PTX/SPIO-SSL were prepared and characterized in vitro. The anti-tumor and diagnostic activity of PTX/SPIO-SSL should be investigated deeply in future study.

Key words: Paclitaxel, Super-paramagnetic iron oxide nanoparticles, Sterically stabilized liposomes, Theranostics

CLC Number:

R944

Supporting:

Wei Ren, Shuang Zhang, Ting Zhong, Dan Huang, Xin Yao, Yang Guo, Xiaochuan Duan, Yifan Yin, Shushi Zhang, Xuan Zhang. The preparation and characteristics of sterically stabilized liposomes containing paclitaxel and super-paramagnetic iron oxide nanoparticles[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 570-575.

References

[1] Yoo, D.; Lee, J.H.; Shin, T.H.; Cheon, J. Acc. Chem. Res. 2011, 44, 863-874.
[2] Schleich, N.; Danhier, F.; Preat, V. J. Control. Release. 2015, 198, 35-54.
[3] Bennett, K.M.; Jo, J.; Cabral, H.; Bakalova, R.; Aoki, I. Adv. Drug. Deliv. Rev. 2014, 74, 75-94.
[4] Lam, T.; Pouliot, P.; Avti, P.K.; Lesage, F.; Kakkar, A.K. Adv. Colloid. Interface. Sci. 2013, 199-200, 95-113.
[5] Mahmoudi, M.; Sant, S.; Wang, B.; Laurent, S.; Sen, T. Adv. Drug. Deliv. Rev. 2011, 63, 24-46.
[6] Zhou, H.; Qian, W.; Uckun, F.M.; Wang, L.; Wang, Y.A.; Chen, H.; Kooby, D.; Yu, Q.; Lipowska, M.; Staley, C.A.; Mao, H.; Yang, L. ACS Nano. 2015, 9, 7976-7991.
[7] Zarrin, A.; Sadighian, S.; Rostamizadeh, K.; Firuzi, O.; Hamidi, M.; Mohammadi-Samani, S.; Miri, R. Int. J. Pharm. 2015, 500, 62-76.
[8] Wang, D.; Fei, B.; Halig, L.V.; Qin, X.; Hu, Z.; Xu, H.; Wang, Y.A.; Chen, Z.; Kim, S.; Shin, D.M.; Chen, Z.G. ACS Nano. 2014, 8, 6620-6632.
[9] Hsiao, J.K.; Wu, H.C.; Liu, H.M.; Yu, A.; Lin, C.T. Nanomedicine. 2015, 11, 1425-1434.
[10] Clares, B.; Biedma-Ortiz, R.A.; Sáez-Fernández, E.; Prados, J.C.; Melguizo, C.; Cabeza, L.; Ortiz, R.; Arias, J.L. Eur. J. Pharm. Biopharm. 2013, 85, 329-338.
[11] Zhang, J.Q.; Zhang, Z.R.; Yang, H.; Tan, Q.Y.; Qin, S.R.; Qiu, X.L. Pharm. Res. 2005, 22, 573-583.
[12] Chen, Y.; Chen, Y.; Xiao, D.; Bose, A.; Deng, R.; Bothun, G.D. Colloids Surf. B Biointerfaces. 2014, 116, 452-458.
[13] Di Corato, R.; Béalle, G.; Kolosnjaj-Tabi, J.; Espinosa, A.; Clément, O.; Silva, A.K.A.; Ménager, C.; Wilhelm, C. ACS Nano. 2015, 9, 2904-2916.
[14] Guo, H.; Chen, W.; Sun, X.; Liu, Y. N.; Li, J.; Wang, J. Carbohydr Polym. 2015, 118, 209-217.
[15] Wang, L.; Zhang, P.; Shi, J.; Hao, Y.; Meng, D.; Zhao, Y.; Yanyan, Y.; Li, D.; Chang, J.; Zhang, Z. ACS Appl. Mater. Interfaces. 2015, 7, 5736-5747.
[16] Luo, L.; Huang, Y.; Zhao, B.; Zhao, X.; Duan, Y.; Du, R.; Yu, K.; Song, P.; Zhao, Y.; Zhang, X.; Zhang, Q. Biomaterials. 2013, 34, 1102-1114.
[17] Zhao, Y.; Ren, W.; Zhong, T.; Zhang, S.; Huang, D.; Guo, Y.; Yao, X.; Wang, C.; Zhang, W.Q.; Zhang, X.; Zhang, Q. J. Control. Release. 2016, 222, 56-66.
[18] Zhao, B.; Zhao, Y.; Huang, Y.; Luo, L.; Song, P.; Wang, X.; Chen, S.; Yu, K.; Zhang, X.; Zhang, Q. Biomaterials. 2012, 33, 2508-2520.
[19] Feng, B.; Hong, R.Y.; Wang, L.S.; Guo, L.; Li, H.Z.; Ding, J.; Zheng, Y.; Wei, D.G. Colloids Surf. A Physicochemical Engineering Aspects. 2008, 328, 52-59.
[20] Martina, M.S.; Fortin, J.P.; Menager, C.; Clement, O.; Barratt, G.; Grabielle-Madelmont, C.; Gazeau, F.; Cabuil, V.; Lesieur, S. J. Am. Chem. Soc. 2005, 127, 10676-10685.
[21] Ferrucci, J.T. Keio J. Med. 1991, 40, 206-214.
[22] Zhang, L.; Zhou, H.; Belzile, O.; Thorpe, P.; Zhao, D. J. Control. Release. 2014, 183, 114-123.
[23] Calle, D.; Negri, V.; Ballesteros, P.; Cerdan, S. Theranostics. 2015, 5, 489-503.
[24] Meier, S.; Putz, G.; Massing, U.; Hagemeyer, C.E.; von Elverfeldt, D.; Meissner, M.; Ardipradja, K.; Barnert, S.; Peter, K.; Bode, C.; Schubert, R.; von Zur, M.C. Biomaterials. 2015, 53, 137-148.
[25] Bothun, G.D.; Lelis, A.; Chen, Y.; Scully, K.; Anderson, L.E.; Stoner, M.A. Nanomedicine. 2011, 7, 797-805.

The preparation and characteristics of sterically stabilized liposomes containing paclitaxel and super-paramagnetic iron oxide nanoparticles

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yusheng Pei, Tong Cai, Guolai Zhang, Chen Chen, Hua Gao. Detection of bacterial endotoxin in paclitaxel liposome [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 436-441.
[2]	Xiaoyou Qu, Yang Zou, Yao Jin, Yuanhang Zhou, Ziqi Wang, Chuyu He, Yunqiang Deng, Xinru Li, Yanxia Zhou, Yan Liu. Preparation and in vitro characterization of paclitaxel-loaded pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-vitamin E succinate [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(8): 582-588.
[3]	Xin Li, Ning Pang, Ji Li, Xianrong Qi. Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(7): 521-527.
[4]	Jing Sun, Wenbing Dai, Zhe Liang, Zhaoyang Wang, Changsheng Huang, Bing He, Hua Zhang, Xueqing Wang, Qiang Zhang. Advances in the formulation and delivery technology of paclitaxel for injection [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(8): 487-500.
[5]	Wenjie Hou, Hua Zheng, Jiancheng Wang. Vapreotide-modified nanomicelle as a targeted nanocarrier for delivering paclitaxel to the tumors with overexpression of somatostatin receptors [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(8): 501-513.
[6]	Yu Sun, Xinming Zhang, Lin Tang. Preparation, optimization and in vitro evaluation of core-shell paclitaxel-loaded nanoparticles composed of MPEG-PLA and PLA [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(2): 104-110.
[7]	Zhanzhang Wang, Zhenzhen Yang, Xianrong Qi^*. Hematological and pathological toxicity of anti-HER2/neu peptide mimetic modified paclitaxel bovine serum albumin nanoparticles [J]. , 2013, 22(5): 441-448.
[8]	Junchao Shao, Haixia Lin^*, Yongmei Cui, Shaoman Yin, Erwin G Van Meir, Jiachen Huang. Design, synthesis and evaluation of the cytotoxicity of a N-mustard and paclitaxel conjugate prodrug [J]. , 2013, 22(2): 137-143.
[9]	Hua Zheng, Wenjie Hou, Jiancheng Wang^*, Qiang Zhang. PEG-PCL nanomicelles for cancer theranosis: targeted imaging and drug delivery [J]. , 2012, 21(6): 591-597.
[10]	Jun Qian, Yi-Xuan Wang, Sheng-Min Su, Yun-Qiu Yu^*. Determination of paclitaxel in human plasma by LC-ESI-MS and its application in a pharmacokinetic study [J]. , 2012, 21(4): 304-310.
[11]	Bing-Xiang Zhao, Yue Huang, Li-Min Luo, Xin Zhao, Xin Wang, Su Chen, Ke-Fu Yu, Xuan Zhang^*, Qiang Zhang . Anti-tumor efficiency of NGR-modified PEG-PLGA micelles containing paclitaxel: in vitro and in vivo [J]. , 2012, 21(1): 40-49.
[12]	Jun-Lin Zhang, Wu Jin, Xue-Qing Wang, Jian-Cheng Wang, Xuan Zhang, Qiang Zhang^* . Octreotide modified PEGylated liposomes improved the anticancer efficacy of doxorubicin in somatostatin receptor II positive tumor model [J]. , 2010, 19(5): 363-370.
[13]	Yi-Ning Song, Shuang-Qing Zhang^, Zhen-Qing Zhang^. New progress in the study of poly (L-glutamic acid)-paclitaxel conjugates for cancer treatment [J]. , 2009, 18(3): 201-207.
[14]	Jia-Bei Sun, Xiang-Rui Liu, Jian-Cheng Wang, Wan-Liang Lu, Xuan Zhang*, Qiang Zhang. Preparation, physicochemical characterization and cyctotoxicity of solid dispersion of paclitaxel and polyvinylpyrrolidone [J]. , 2008, 17(2): 113-117.
[15]	Xiang-Rui Liu, Ke-Chun Wu, Chun-Hui Zhang, Xuan Zhang^*, Qiang Zhang. A RP-HPLC method for determination of paclitaxel in its solid dispersion [J]. , 2007, 16(2): 101-104.